Market Exclusive

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (NASDAQ:MDRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (NASDAQ:MDRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers

(e) At the Annual Meeting of Stockholders held on May 22, 2017,
the stockholders of Allscripts Healthcare Solutions, Inc. (the
Company) approved the second amendment and restatement of the
Companys 2011 Stock Incentive Plan (the Second Amended and
Restated 2011 Plan), which had been previously approved by the
Board of Directors, subject to stockholder approval. The
amendment increases the available shares under the 2011 Stock
Incentive Plan by 7,500,000 shares. In addition, the Second
Amended and Restated 2011 Stock Incentive Plan prohibits the
payment of dividends on unvested awards and extends the
expiration date of the plan. The foregoing summary is qualified
in its entirety by reference to the complete text of the Second
Amended and Restated 2011 Plan, a copy of which is filed as
Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated by reference herein.

Item 5.07

Submission of Matters to a Vote of Security Holders

At the 2017 Annual Meeting held on May 22, 2017, the stockholders
of the Company voted on the following five proposals and cast
their votes as described below:

1.

The individuals listed below were elected at the 2017
Annual Meeting to serve as directors of the Company until
the next annual meeting of stockholders and until their
successors are duly elected and qualified.

For

Against

Abstain

Broker Non-Vote

Mara G. Aspinall

155,501,074

1,997,000

581,820

16,062,719

Paul M. Black

156,805,703

698,827

575,364

16,062,719

P. Gregory Garrison

156,814,379

675,370

590,145

16,062,719

Jonathan J. Judge

156,373,618

1,115,102

591,174

16,062,719

Michael A. Klayko

156,374,404

1,115,877

589,613

16,062,719

Yancey L. Spruill

156,821,648

666,913

591,333

16,062,719

Dave B. Stevens

156,804,452

684,498

590,945

16,062,719

David D. Stevens

156,802,585

685,128

592,181

16,062,719

Ralph H. Thurman

156,327,917

1,162,613

589,364

16,062,719

2.

A management proposal to approve an amendment and
restatement of the Companys 2011 Stock Incentive Plan to,
among other things, increase the number of shares
available for grant thereunder, as described in the proxy
materials, was approved.

For

Against

Abstain

Broker Non-Vote

136,094,963

21,407,042

577,889

16,062,719

3.

A management proposal to ratify the appointment of Grant
Thornton LLP as the Companys independent registered
public accounting firm for the fiscal year ending
December 31, 2017, as described in the proxy materials,
was approved.

For

Against

Abstain

Broker Non-Vote

172,558,543

992,417

591,653

4.

A non-binding, advisory resolution to approve named
executive officer compensation, as described in the proxy
materials, was approved.

For

Against

Abstain

Broker Non-Vote

147,327,006

10,131,795

621,093

16,062,719

5.

Stockholders approved, on an advisory basis, the holding
of an advisory vote every year on the compensation of the
Companys executive officers. Based on these results, the
Company decided that it will hold an advisory vote on the
compensation of the Companys executive officers every
year. The voting results were as follows.

One Year

Two Years

Three Years

Abstain

Broker Non-Vote

140,000,359

49,143

17,423,260

607,132

16,062,719

Item 7.01

Regulation FD Disclosure

On May 24, 2017, the Company issued a press release announcing
the election of Mara G. Aspinall to serve as director. A copy of
the press release is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated herein by reference.

The information furnished to this Item shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or incorporated by reference
in any filing under the Securities Act of 1933, as amended, or
the Exchange Act.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number

Description

10.1

Allscripts Healthcare Solutions, Inc. Second Amended and
Restated 2011 Stock Incentive Plan

99.1

Press Release by Allscripts Healthcare Solutions, Inc.
dated May 24, 2017

About ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (NASDAQ:MDRX)
Allscripts Healthcare Solutions, Inc. delivers information technology (IT) and services to help healthcare organizations in clinical, financial and operational results. The Company operates through two segments: Clinical and Financial Solutions, and Population Health. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record (EHR)-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services. Its Population Health segment includes sale of health management and coordinated care solutions that are focused on hospitals, health systems, other care facilities and accountable care organizations. These solutions enable clients to connect, transition, analyze, and coordinate care across the care community. ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (NASDAQ:MDRX) Recent Trading Information
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (NASDAQ:MDRX) closed its last trading session down -0.34 at 11.41 with 2,046,961 shares trading hands.

Exit mobile version